Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Stock Report

| More

Cipla acquires novel anti-infective Elores to further antimicrobial stewardship in critical care in India

Posted On: 2019-10-17 21:42:18

Cipla Limited (BSE: 500087; NSE: CIPLA EQ; hereafter referred to as "Cipla") announces the acquisition of a novel and patented anti-infective product, Elores, from Venus Remedies Limited ("VRL") for the Indian market to further strengthen its presence in the branded Indian critical care space and as a part of its agenda to contribute to the fight against Anti-Microbial Resistance (AMR).

Elores is a novel combination of Ceftriaxone (a third generation beta-lactam cephalosporin), Sulbactam (a beta-lactamase inhibitor) and Disodium EDTA (an Antibiotic Resistance Breaker) indicated for the treatment of life threatening infections caused by gram-negative bacteria. It preserves the efficacy of the antibiotic using appropriate Antibiotic Resistance Breakers (ARBs). The product was launched in India across select tertiary care hospitals in the country in 2013 after approval from the Drug Controller General of India.

AMR has emerged as a critical threat to public health. At the present rate, it is estimated that as many as 10 million individuals worldwide could die annually from complications related to AMR. India carries one of the largest burdens of drug-resistant pathogens worldwide. In India, Cipla has a long history of antibiotic development from ampicillin in the 1970s to quinolones in the 1990s. More recently, Cipla introduced the extremely effective antibiotic colistin in India. Today, Cipla is the market leader in the anti-infectives segment in India, and has a large portfolio of oral and injectable anti-microbial brands that serve over 20 million patients every year. Elores will strengthen Cipla's play in branded anti-infectives. With the view to partner with patients and physicians in infection management, Cipla recently launched the 'Save Susceptibility' campaign to build awareness, enable better diagnosis and enable appropriate action and use of anti-microbials.

Umang Vohra, Managing Director and Global Chief Executive Officer, Cipla, said: "Cipla has consistently been at the forefront of promoting rational and judicious use of antibiotics, and has been a leading industry voice in the fight against AMR. Elores underscores our commitment to anti-microbial stewardship and is a significant addition to our branded portfolio of anti-infectives in India. We recently acquired ZEMDRI™, and with the acquisition of Elores, we have added to our offering of new generation antibiotics. In keeping with our purpose of Caring for Life, Elores will improve patient access to innovative quality medicines and help patients battle life-threatening resistance at critical junctures."

Saransh Chaudhary, CEO, Venus Medicine Research Centre, said: "VRL has been leading the research on novel anti-infectives in India. We've always viewed anti-microbial resistance (AMR) as a huge public health crisis that needs to be dealt with immediately and at all levels of the healthcare setup. Elores was our response to the problem and it has been very satisfying to see the difference that it has made in the lives of patients. I'm positive that Cipla will expand the reach of Elores to many more patients in India while ensuring a similar commitment to anti-microbial stewardship. AMR continues to be the core focus for us going forward and we hope that our consistent efforts in this space will lead to better outcomes for patients dealing with life-threatening infections."

Shares of CIPLA LTD. was last trading in BSE at Rs.446.3 as compared to the previous close of Rs. 446.55. The total number of shares traded during the day was 145166 in over 2559 trades.

The stock hit an intraday high of Rs. 447.5 and intraday low of 439.5. The net turnover during the day was Rs. 64154873.

Shares of VENUS REMEDIES LTD. was last trading in BSE at Rs.29.05 as compared to the previous close of Rs. 26.15. The total number of shares traded during the day was 163630 in over 1000 trades.

The stock hit an intraday high of Rs. 31.35 and intraday low of 27.3. The net turnover during the day was Rs. 4967522.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

Sterling Tools Ltd consolidated Q2 PAT slides to Rs. 7.01 crores

Ishan Dyes & Chemicals Ltd reports Rs. 1.94 crore PAT in Q2 FY20

Archidply Industries Ltd posts higher PAT of Rs. 1.47 crore in Q2

J Kumar Infraprojects Ltd Q2 standalone PAT rises to Rs. 55.90 crores

Vardhman Holdings Ltd Q2 consolidated PAT declines to Rs. 28.88 crores

Jaysynth Dyestuff India Ltd reports net profit of Rs. 0.61 crore in Q2

Future Lifestyle Fashions Ltd consolidated net profit at Rs. 11.87 crores in Q2

Creative Castings Ltd posts Q2 FY2019-20 net profit of Rs. 0.84 crore

Neuland Laboratories Ltd Q2 consolidated PAT jumps to Rs. 8.68 crores

Surya Roshni Ltd posts standalone PAT of Rs. 22.62 crores in Q2

Suryaamba Spinning Mills Ltd posts higher Q2 PAT of Rs. 1.32 crore in Q2

Surbhi Industries Ltd Q2 net profit at Rs. 0.55 crore

Eldeco Housing & Industries Ltd Q2 consolidated PAT at Rs. 8.23 crores

Paul Merchants Ltd consolidated Q2 net profit at Rs. 5.46 crores

Superhouse Ltd Q2 PAT at Rs. 7.60 crores

Jamna Auto Industries Ltd Q2 PAT plunges to Rs. 6.36 crores

Apollo Micro Systems Ltd Q2 PAT slides to Rs. 2.89 crores

Bannari Amman Spinning Mills Ltd posts consolidated PAT of Rs. 4.06 crores in Q2 FY20

IMPAL Q2 consolidated PAT rises to Rs. 15.75 crores

Ganga Papers India Ltd Q2 net profit at Rs. 0.41 crore

Nectar Lifesciences Ltd consolidated Q2 net profit at Rs. 2.45 crores

Action Construction Equipment Ltd Q2 consolidated net profit at Rs. 14.31 crores

Dhunseri Tea & Industries Ltd Q2 consolidated net profit at Rs. 95 crores

Premier Explosives Ltd consolidated Q2 net profit at Rs. 0.87 crore

Taparia Tools Ltd Q2 net profit at Rs. 7.28 crores

Dilip Buildcon Ltd consolidated Q2 net profit declines to Rs. 28.61 crores

Jyoti Resins & Adhesives Ltd Q2 net profit at Rs. 2.32 crore

Source Natural Foods & Herbal Suppl Ltd Q2 net profit at Rs. 0.24 crore

Denis Chem Lab Ltd posts net profit of Rs. 0.83 crore in Q2 FY20

KNR Constructions Ltd consolidated Q2 PAT at Rs. 85.90 crores

Apollo Hospitals Enterprise Ltd consolidated Q2 net profit up at Rs. 86.24 crores

Mansi Finance Chennai Ltd Q2 net profit lower at Rs. 0.44 crore

STL Global Ltd Q2 PAT at Rs. 0.21 crore

Maharashtra Seamless Ltd reports Rs. 185.04 crores consolidated net profit in Q2

B & A Ltd consolidated Q2 PAT rises to Rs. 17.51 crores

Valson Industries Ltd Q2 net profit at Rs. 0.25 crore

Remi Sales & Engineering Ltd Q2 net profit declines to Rs. 1.11 crore

Satia Industries Ltd reports PAT of Rs. 25.04 crores in Q2 FY20

APM Industries Ltd Q2 net profit falls to Rs. 1.60 crore

Mysore Petro Chemicals Ltd posts consolidated net profit of Rs. 0.57 crore in Q2

Fenoplast Ltd posts surge in net profit to Rs. 0.35 crore in Q2

Navkar Corporation Ltd Q2 FY 2019-20 net profit jumps YoY

BF Investment Ltd Q2 FY20 consolidated net profit up QoQ to Rs. 38.50 crores

Gujarat Themis Biosyn Ltd posts net profit of Rs. 1.60 crore in Q2

PFC Q2 consolidated PAT at Rs. 1870.71 crores

NCL Industries Ltd Q2 net profit at Rs. 8.74 crores

Ester Industries Ltd Q2 net profit at Rs. 19.24 crores

Navkar Builders Ltd reports jump in net profit to Rs. 0.77 crore in Q2

Gateway Distriparks Ltd consolidated Q2 PAT slips to Rs. 17.38 crores

HIL Ltd Q2 PAT rises YoY to Rs. 31.94 crores







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019